Skip links

Akari TX

Main navigation

Menu

Investor Relations

Investor Relations

Akari Therapeutics is an innovative targeted oncology company built on next generation antibody-drug conjugates (ADC) and a novel discovery engine

Data as of
Copyright Refinitiv. Minimum 15 minutes delayed.
Refresh quote

PRESS RELEASES

  • December 18, 2024
    Summary ToggleAkari Therapeutics Announces Key Leadership Appointments
    Samir R. Patel, M.D., appointed as Chief Executive Officer Abizer Gaslightwala appointed to Board of Directors BOSTON and LONDON, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) today announced the appointment of Samir R. Patel, M.D., as Chief Executive Officer, effective
  • December 16, 2024
    Summary ToggleAkari Therapeutics Appoints Torsten Hombeck, Ph.D. as Chief Financial Officer
    BOSTON and LONDON, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) today announced the appointment of Torsten Hombeck, Ph.D. as Chief Financial Officer, effective December 16, 2024. Dr. Hombeck is a seasoned executive with over 20 years of experience in the biotechnology
  • November 19, 2024
    Summary ToggleAkari Therapeutics Regains Full Nasdaq Compliance
    - Shareholders Equity Deficiency has been Cured - - Akari will Continue to be Listed and Traded on The Nasdaq Stock Market - BOSTON and LONDON, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) announces receipt of written notice from the Listing Qualifications Staff of The
View All Releases

LATEST PRESENTATIONS

View All Presentations
Tools